Literature DB >> 12167343

Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.

Eva Kehmeier1, Heiko Rühl, Britta Voland, Melissa Conrad Stöppler, Elliot Androphy, Hubert Stöppler.   

Abstract

The group of mucosal epithelia-infecting human papillomaviruses (HPV) can be subdivided in "low" and "high risk" HPV types. Both types induce benign neoplasia (condyloma), but only the infection with a "high risk" HPV type is causally associated with an increased risk of developing anogenital tumors. The oncogenic potential of high risk HPVs resides at least partially in the viral E6 protein. The E6 protein targets the cellular p53 protein for proteasome-dependent degradation, which is associated with the immortalizing and transforming functions of these viruses. Recently the E6-dependent proteasome-mediated destabilization of additional cellular proteins (E6TP1, c-myc, Bak, hMCM7, human scribble, E6AP, MAGI-1) has been described, but the cellular mechanisms controlling the viral E6 protein stability itself have been so far not analyzed. In this study, we transiently expressed the E6 genes of the high risk HPV type 16, the low risk HPV types 6a and 11, and the cutaneous epithelia-infecting HPV types 5 and 8 from a eucaryotic expression vector and compared the cellular steady-state levels of the expressed E6 proteins. We demonstrated that the high risk HPV 16 E6 protein possesses the lowest steady-state level in comparison to the low risk HPV type E6 proteins and the cutaneous epithelia-infecting HPV type E6 proteins. Inhibition of cellular proteasome-dependent protein degradation led to an increase in steady-state levels of high risk but not of low risk E6 proteins. Analysis of functionally deficient HPV 16 E6 proteins in p53 null- and p53 wild-type-expressing cell lines revealed that the cellular steady-state level of this protein is influenced neither by its p53- nor its E6AP-binding abilities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167343     DOI: 10.1006/viro.2002.1502

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.

Authors:  Thibault Mesplède; David Gagnon; Fanny Bergeron-Labrecque; Ibrahim Azar; Hélène Sénéchal; François Coutlée; Jacques Archambault
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Low risk HPV-6E6 induces apoptosis in bone marrow-derived dendritic cells.

Authors:  Lina Sun; Lei Zhao; Dan Li; Shuai Xu; Xuexin Hou; Zhenjun Li
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

3.  The SMAD2/3 pathway is involved in hepaCAM-induced apoptosis by inhibiting the nuclear translocation of SMAD2/3 in bladder cancer cells.

Authors:  Xiaorong Wang; E Chen; Min Tang; Xue Yang; Yin Wang; Zhan Quan; Xiaohou Wu; Chunli Luo
Journal:  Tumour Biol       Date:  2016-02-12

4.  Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6.

Authors:  Rébécca Phaeton; Matthew Harris; Zewei Jiang; Xing Guo Wang; Mark H Einstein; Gary L Goldberg; Arturo Casadevall; Ekaterina Dadachova
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

5.  The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase.

Authors:  Melissa L Kelley; Kerri E Keiger; Chan Jae Lee; Jon M Huibregtse
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.

Authors:  Rébécca Phaeton; Xing Guo Wang; Mark H Einstein; Gary L Goldberg; Arturo Casadevall; Ekaterina Dadachova
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

7.  PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18 E6.

Authors:  Carina H Storrs; Saul J Silverstein
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

8.  Control of alpha subunit of eukaryotic translation initiation factor 2 (eIF2 alpha) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2 alpha-dependent gene expression and cell death.

Authors:  Shirin Kazemi; Stavroula Papadopoulou; Suiyang Li; Qiaozhu Su; Shuo Wang; Akihiko Yoshimura; Greg Matlashewski; Thomas E Dever; Antonis E Koromilas
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

9.  The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability.

Authors:  Robin M Vos; Jennifer Altreuter; Elizabeth A White; Peter M Howley
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

10.  Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.

Authors:  Matthew Harris; Xing Guo Wang; Zewei Jiang; Gary L Goldberg; Arturo Casadevall; Ekaterina Dadachova
Journal:  Head Neck Oncol       Date:  2011-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.